Is bluebird bio a Buy?
Investing in biotech stocks isn't for the faint of heart. These companies often boast one (or more) potential blockbuster drugs, but a single misstep on the path to approval -- such as a negative clinical trial result or a regulatory setback -- can send their share prices crashing. Still, if you pick a biotech that finds success, your investment can pay rich dividends. With that in mind, let's turn our attention to one that has been making a lot of noise in 2019: bluebird bio (NASDAQ: BLUE). Is it a buy?
Bluebird focuses on treatments that employ gene therapy. Technical details aside, such therapies aim to replace or supplement the defective genes that cause certain illnesses with their healthy versions. Scientists have been working to turn these techniques into safe, effective treatments for years, but manipulating the basic building blocks of life in this way is no simple exercise. However, gene therapy offers the potential to cure conditions that are otherwise extremely difficult -- if not impossible -- to treat via other means.
Image Source: Getty Images.
Source Fool.com
